Business

Shionogi acquires global RADICAVA rights from Tanabe Pharma for USD 2.5b

Shionogi Acquires Global RADICAVA Rights for USD 2.5 Billion from Tanabe Pharma Corporation

Edited by Robert McTiernan··3 min read

Shionogi & Co., Ltd. has completed the acquisition of Radicava (edaravone) from Tanabe Pharma Corporation, taking rights "in major countries" with "transfer of rights in additional countries and regions forthcoming". The transaction involves a lump sum payment of USD 2.5 billion, with potential additional royalties on future sales subject to undisclosed conditions. The transaction consolidates an FDA-approved ALS franchise into Shionogi's portfolio and establishes a US rare disease commercial infrastructure aligned with the company's stated 2030 strategic objectives.

Shionogi paid the USD 2.5 billion upfront through its US subsidiary, Shionogi Inc. The transaction, first announced in December 2025, is expected to be immediately accretive in fiscal year 2026, contributing approximately USD 700 million in annual global sales. Transfer of rights across all major countries and regions was confirmed complete as of April 1, 2026, with residual territory transfers forthcoming.

Edaravone and the oral reformulation

The acquired franchise centres on edaravone, a small molecule free radical scavenger that neutralizes reactive oxygen species (ROS) implicated in oxidative stress-driven motor neuron degeneration in ALS. The compound functions as a neuroprotective antioxidant, though its precise mechanism of action in ALS has not been fully elucidated. Tanabe Pharma initiated ALS research in 2001 and developed edaravone through an iterative clinical programme spanning 13 years, culminating in approval as Radicut in Japan and South Korea in 2015 and FDA approval of the intravenous formulation in May 2017, the first novel ALS therapy approved in the US in over two decades at that time.

The primary commercial asset is Radicava ORS (edaravone oral suspension, 105 mg / 5 mL), approved by the FDA on May 12, 2022. In 2024, the FDA granted Radicava ORS Orphan Drug Exclusivity on the basis of its major contribution to patient care, specifically its oral route of administration, which eliminates the clinical and logistical burden of intravenous infusion for a patient population with progressive motor impairment. The dosing schedule follows a 14-day on / 14-day off cycle, administered after overnight fasting. The oral formulation has supplanted the IV product as the primary US commercial vehicle, with Radicava ORS and the legacy IV formulation collectively used to treat over 22,000 patients in the US across more than 2.8 million days of therapy, prescribed by over 2,800 healthcare providers.

The AllSci BriefSystematic R&D and deal news. Daily.

Strategic outlook

The transaction gives Shionogi an established US rare disease commercial platform at scale, a capability the company has been building toward as part of its 2030 Vision. More than 100 employees from Tanabe Pharma America transitioned to Shionogi, bringing with them existing payer relationships, ALS community networks, and rare disease operational infrastructure. This human capital component is structurally significant: rare disease commercialisation depends on specialist field teams with established relationships among a concentrated prescriber base, and building such capacity organically would require considerable time and investment. Shionogi's existing US rare disease pipeline includes clinical programs in Fragile X syndrome, Jordan's Syndrome, and Pompe disease.

For Tanabe Pharma, the divestiture of Radicava follows a period of restructuring within the Mitsubishi Chemical Holdings group and represents a full exit from the asset it originated, retaining only a conditional royalty interest on future sales.

Spot something wrong? Report an issue with this article